Page last updated: 2024-09-05

lapatinib and gsk 1363089

lapatinib has been researched along with gsk 1363089 in 11 studies

Compound Research Comparison

Studies
(lapatinib)
Trials
(lapatinib)
Recent Studies (post-2010)
(lapatinib)
Studies
(gsk 1363089)
Trials
(gsk 1363089)
Recent Studies (post-2010) (gsk 1363089)
1,9193051,4421319124

Protein Interaction Comparison

ProteinTaxonomylapatinib (IC50)gsk 1363089 (IC50)
Epidermal growth factor receptorHomo sapiens (human)1.5147
High affinity nerve growth factor receptorHomo sapiens (human)0.003
Acyl-CoA desaturase 1Rattus norvegicus (Norway rat)0.0004
Hepatocyte growth factor receptorHomo sapiens (human)0.056
Proto-oncogene tyrosine-protein kinase ROSHomo sapiens (human)0.01
Platelet-derived growth factor receptor betaHomo sapiens (human)0.0098
Mast/stem cell growth factor receptor KitHomo sapiens (human)0.1814
Platelet-derived growth factor receptor alphaHomo sapiens (human)0.2346
Vascular endothelial growth factor receptor 1 Homo sapiens (human)0.2541
Ephrin type-A receptor 2Homo sapiens (human)0.0019
Tyrosine-protein kinase receptor UFOHomo sapiens (human)0.0417
Delta-type opioid receptorMus musculus (house mouse)0.0049
Vascular endothelial growth factor receptor 3Homo sapiens (human)0.003
Vascular endothelial growth factor receptor 2Homo sapiens (human)0.1234
Receptor-type tyrosine-protein kinase FLT3Homo sapiens (human)0.1806
Kappa-type opioid receptorCavia porcellus (domestic guinea pig)2.99
Mu-type opioid receptorMus musculus (house mouse)0.0056
4-aminobutyrate aminotransferase, mitochondrialMus musculus (house mouse)0.0086
Angiopoietin-1 receptorHomo sapiens (human)0.0011
Macrophage-stimulating protein receptorHomo sapiens (human)0.1798
Homeodomain-interacting protein kinase 1Homo sapiens (human)0.1
Cyclin-dependent kinase-like 3Homo sapiens (human)7.9
Homeodomain-interacting protein kinase 4Homo sapiens (human)0.1
Homeodomain-interacting protein kinase 2Homo sapiens (human)0.1
Homeodomain-interacting protein kinase 3Homo sapiens (human)0.1
ALK tyrosine kinase receptorHomo sapiens (human)3.18

Research

Studies (11)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (9.09)29.6817
2010's9 (81.82)24.3611
2020's1 (9.09)2.80

Authors

AuthorsStudies
Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP1
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP1
Liu, Y; Xu, Z; Zhao, SJ1
Annan, R; Gilmer, TM; Greger, J; Greshock, J; Halsey, W; Liu, L; Liu, Y; Martin, AM; Sathe, GM; Shi, H1
Anderson, A; Gilmer, TM; Greger, J; Liu, L; Liu, Y; Martin, AM; Peterson, J; Shi, H1
Lou, L; Quan, H; Wang, L; Wang, Q; Xie, C; Zhao, J1
Axel, U; Baska, F; Greff, Z; Gyulavári, P; Ibolya, K; Kéri, G; Orfi, L; Peták, I; Szántai, KC; Szokol, B; Vantus, T; Zoltán, O1
Bradbury, P; Chia, SK; Eisenhauer, E; Ellard, SL; Gelmon, K; Goodwin, R; Hagerman, L; Kumar, V; Lohrisch, C; Mates, M; Mihalcioiu, C; Miller, WH; Sakashita, S; Taylor, S; Tsao, MS; Wang, T; Welch, S1
Awasthi, N; Hassan, MS; Li, J; Schwarz, MA; Schwarz, RE; von Holzen, U; Williams, F1
Al-Shakliah, NS; Bakheit, AH; Darwish, HW; Darwish, IA1

Reviews

1 review(s) available for lapatinib and gsk 1363089

ArticleYear
1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.
    European journal of medicinal chemistry, 2019, Dec-01, Volume: 183

    Topics: Antineoplastic Agents; Humans; Molecular Structure; Neoplasms; Structure-Activity Relationship; Triazoles

2019

Trials

1 trial(s) available for lapatinib and gsk 1363089

ArticleYear
A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer.
    Breast cancer research : BCR, 2017, 05-02, Volume: 19, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Combined Chemotherapy Protocols; Axl Receptor Tyrosine Kinase; Breast Neoplasms; Disease-Free Survival; Female; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Quinazolines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Vascular Endothelial Growth Factor Receptor-1

2017

Other Studies

9 other study(ies) available for lapatinib and gsk 1363089

ArticleYear
Comprehensive analysis of kinase inhibitor selectivity.
    Nature biotechnology, 2011, Oct-30, Volume: 29, Issue:11

    Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity

2011
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013
The target landscape of clinical kinase drugs.
    Science (New York, N.Y.), 2017, 12-01, Volume: 358, Issue:6367

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays

2017
Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL.
    Cancer research, 2009, Sep-01, Volume: 69, Issue:17

    Topics: Anilides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axl Receptor Tyrosine Kinase; Breast Neoplasms; Cell Line, Tumor; Clone Cells; Drug Antagonism; Drug Resistance, Neoplasm; Female; Genes, erbB-2; Humans; Lapatinib; Oncogene Proteins; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Quinazolines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptors, Estrogen; RNA, Small Interfering; Trastuzumab

2009
Synergistic effects of foretinib with HER-targeted agents in MET and HER1- or HER2-coactivated tumor cells.
    Molecular cancer therapeutics, 2011, Volume: 10, Issue:3

    Topics: Anilides; Antibodies, Monoclonal; Apoptosis; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Hepatocyte Growth Factor; Humans; Immunoprecipitation; Lapatinib; Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-met; Quinazolines; Quinolines; Receptor, ErbB-2; Receptors, Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction

2011
RON confers lapatinib resistance in HER2-positive breast cancer cells.
    Cancer letters, 2013, Oct-28, Volume: 340, Issue:1

    Topics: Anilides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Crizotinib; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Gene Knockdown Techniques; Humans; Inhibitory Concentration 50; Lapatinib; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Pyrazoles; Pyridines; Quinazolines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Signal Transduction; Trastuzumab

2013
[Development and biochemical characterization of EGFR/c-Met dual inhibitors].
    Acta pharmaceutica Hungarica, 2013, Volume: 83, Issue:4

    Topics: Afatinib; Aminopyridines; Anilides; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Line, Tumor; Computer Simulation; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Imidazoles; Lapatinib; Lung Neoplasms; Molecular Structure; Protein Kinase Inhibitors; Protein Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-met; Pyrazines; Pyrazoles; Pyridines; Pyridones; Quinazolines; Quinolines

2013
Combination effect of lapatinib with foretinib in HER2 and MET co-activated experimental esophageal adenocarcinoma.
    Scientific reports, 2019, 11-26, Volume: 9, Issue:1

    Topics: Adenocarcinoma; Anilides; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carboplatin; Cell Line, Tumor; Esophageal Neoplasms; Female; Humans; Lapatinib; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Neoplasm Proteins; Paclitaxel; Peritoneal Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-met; Quinolines; Random Allocation; Receptor, ErbB-2; Tumor Burden; Xenograft Model Antitumor Assays

2019
Development of innovative artificial neural networks for simultaneous determination of lapatinib and foretinib in human urine by micellar enhanced synchronous spectrofluorimetry.
    Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 2020, Sep-05, Volume: 238

    Topics: Anilides; Humans; Lapatinib; Limit of Detection; Micelles; Neural Networks, Computer; Protein Kinase Inhibitors; Quinolines; Spectrometry, Fluorescence

2020